C3 Jian is a clinical-stage biotechnology company developing and commercializing novel products to diagnose, treat and prevent diseases related to the human microbiome, with an initial focus on improving oral health.
From C3 Jian:
LOS ANGELES, Calif. — C3 Jian, Inc., a private company focused on developing proprietary drugs with an initial focus on improving oral healthcare, announced today the close of its Series D financing raising total proceeds of $60.5 million.
Funds from the financing will be used to support continued clinical development of the Company’s lead product, referred to as C16G2, a proprietary peptide-based antimicrobial drug specifically targeting Streptococcus mutans, a bacterium responsible for dental caries or tooth decay. Under a U.S. FDA Investigational New Drug Application, the Company recently began a Phase 2 Clinical Trial to study C16G2 formulated as a mouth rinse as well as a gel for both dental tray and tooth brush applications. Proceeds received will also help advance development of a second peptide drug candidate that has both teeth remineralization, as well as hair/nail growth properties. In addition, the Company plans to build a pipeline of additional innovative compounds using its proprietary STAMP (Specifically Targeted Antimicrobial Peptide) technology platform. STAMPs have the potential to alter human microbiomes by targeting and eliminating a specific bacterium versus broad spectrum antibiotics. The Company expects to explore development of STAMPs for medical uses in addition to oral healthcare…
READ FULL PRESS RELEASE [web]
Watch video about the technology [web]